Adhesion
0
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Baxter InternationalDEERFIELD, IL
4 programsADEPTN/A1 trial
ADEPTN/A
COSEALN/A
CosealN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PharmasyntezSeroguard
PharmasyntezSeroguard
Baxter InternationalCoseal
Baxter InternationalADEPT
Clinical Trials (4)
Total enrollment: 517 patients across 4 trials
Efficacy and Dose Ranging Study of Seroguard
Start: May 2017Est. completion: Jan 2018114 patients
Phase 2Completed
Safety and Tolerability of Seroguard Use
Start: May 2015Est. completion: Oct 201550 patients
Phase 1Completed
PMCF Study for COSEAL® in Gynecologic Surgery
Start: Jun 2024Est. completion: May 2025200 patients
N/ACompleted
PMCF Study for ADEPT® in LaparoscopicGynecologic Surgery
Start: Jun 2023Est. completion: May 2024153 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.